Results 251 to 260 of about 121,769 (336)

GSK-3 Represses Growth Factor-inducible Genes by Inhibiting NF-κB in Quiescent Cells [PDF]

, 2009
Julie R. Graham, John W. Tullai, Geoffrey M. Cooper   +2 more
openalex   +1 more source

Methotrexate toxicity and intolerance in paediatric inflammatory bowel disease: A retrospective cohort study

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Methotrexate (MTX) is frequently prescribed in paediatric inflammatory bowel disease (IBD), with routine laboratory monitoring to detect adverse events (AEs), such as hepatotoxicity and myelotoxicity. However, data on the incidence and predictors of these AEs remain limited.
Eva Vermeer, Eveline L. Soetens, Eduard A. Struys, Johan E. van Limbergen, Maja Bulatović‐Ćalasan, Robert de Jonge, Nanne K. H. de Boer, Tim G. J. de Meij   +7 more
wiley   +1 more source

Human colorectal cancer: upregulation of the adaptor protein Rai in TILs leads to cell dysfunction by sustaining GSK-3 activation and PD-1 expression. [PDF]

Cancer Immunol Immunother
Montecchi T, Nannini G, De Tommaso D, Cassioli C, Coppola F, Ringressi MN, Carraro F, Naldini A, Taddei A, Marotta G, Amedei A, Baldari CT, Ulivieri C.   +12 more
europepmc   +1 more source

Bis(maltolato)-oxovanadium (IV)-induced phosphorylation of PKB, GSK-3 and FOXO1 contributes toits glucoregulatory responses (Review)

, 2009
Srivastava
openalex   +2 more sources

GSK3β regulates oligodendrogenesis in the dorsal microdomain of the subventricular zone via Wnt-β-catenin signaling [PDF]

, 2014
Azim, Kasum, Butt, Arthur M., Raineteau, Olivier, Rivera, Andrea   +3 more
core   +1 more source

Characteristics of Adult Patients With Atopic Dermatitis Initiating Biologics and Janus Kinase Inhibitors in the CorEvitas Atopic Dermatitis Registry

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Biologics and Janus kinase inhibitors (JAKi) are two advanced systemic treatment options for patients with atopic dermatitis (AD). The decision to initiate one of these therapies is complex and may be driven by many factors.
Eric L. Simpson, Linda Stein Gold, Seemal R. Desai, Alexandra K. Golant, Douglas DiRuggiero, Christian Fenske, Yolanda Muñoz Maldonado, Alvin H. Li, Zach Dawson, Kaylee Ho, Kayla Callahan, Gaia Gallo, Jonathan I. Silverberg   +12 more
wiley   +1 more source

New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa

JEADV Clinical Practice, EarlyView.
ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender, Rosalind Hughes, Brian Kirby   +2 more
wiley   +1 more source

2,5-Dimethylcelecoxib prevents isoprenaline-induced cardiomyocyte hypertrophy and cardiac fibroblast activation by inhibiting Akt-mediated GSK-3 phosphorylation

, 2019
Shoji Morishige, Fumi Takahashi‐Yanaga, Shin Ishikane, Masaki Arioka, Kazunobu Igawa, Akihiro Kuroo, Katsuhiko Tomooka, Akira Shiose, Toshiyuki Sasaguri   +8 more
openalex   +2 more sources

Sacubitril/Valsartan Ameliorates Inflammation and Oxidative Stress in Hypertensive Heart Disease by Upregulating CAMKK2 Protein and Modulating the AMPK/AKT/GSK‐3β Axis

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Sacubitril/valsartan (Sac/Val) has emerged as an effective compound with myocardium‐protective functions in experimental and clinical trials for heart failure. This study investigated the function of Sac/Val in hypertensive heart disease (HHD) and explored the underlying mechanism.
Yan‐Jun Yang, Jiu‐Sheng Li
wiley   +1 more source

Recurrent Respiratory Papillomatosis Foundation Position Statement on the Management of Adults With RRP

The Laryngoscope, EarlyView.
ABSTRACT Objective With regulatory approval of HPV‐specific immunotherapy for recurrent respiratory papillomatosis (RRP) and growing experience with systemic bevacizumab, a management algorithm incorporating these medical treatments is warranted. Data Sources and Methods RRP Foundation (RRPF) Key Opinion Leaders offer a proposed management algorithm ...
Simon R. Best, Aaron D. Friedman, Clark A. Rosen, Robert T. Sataloff, Laura A. Matrka, H. Steven Sims, David E. Rosow, Nabil F. Saba, David G. Lott, Adam M. Klein, Ted Mau, Milan R. Amin, Kathryn A. Wikenheiser‐Brokamp, Scott M. Norberg, Kim McClellan, Geoffrey D. Young, Clint T. Allen, on behalf of the Recurrent Respiratory Papillomatosis Foundation   +17 more
wiley   +1 more source